日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.

一项机会窗口试验揭示了复发性胶质母细胞瘤患者对纳夫特马德林产生反应和耐药性的机制

Rendo Veronica, Lee Eudocia Q, Bossi Connor, Khuu Nicholas, Rudek Michelle A, Pal Sangita, Azazmeh Narmen, Rashid Rumana, Lin Jia-Ren, Cusick Margaret, Reynolds Abigail R N, Fassinou Auriole C R, Ayoub Georges, Malinowski Seth, Lapinskas Emily, Pisano William, Jeang John, Stopka Sylwia A, Regan Michael S, Spetz Johan, Desai Arati, Lieberman Frank, Palanichamy Kamalakannan, Fisher Joy D, Pelton Kristine, Huang Raymond Y, Sarosiek Kristopher A, Nabors Louis B, Holdhoff Matthias, Danda Neeraja, Strowd Roy, Desideri Serena, Walbert Tobias, Ye Xiaobu, Chakravarti Arnab, Sorger Peter K, Santagata Sandro, Agar Nathalie Y R, Grossman Stuart A, Alexander Brian M, Wen Patrick Y, Ligon Keith L, Beroukhim Rameen

A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

MLN4924 和贝利司他治疗复发/难治性急性髓系白血病或骨髓增生异常综合征的 I 期研究

Maher, Keri R; Shafer, Danielle; Schaar, Dale; Bandyopadhyay, Dipankar; Deng, Xiaoyan; Wright, John; Piekarz, Richard; Rudek, Michelle A; Harvey, R Donald; Grant, Steven

A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors

一项针对晚期实体瘤患者的 I 期研究,评估 BH3 模拟物 navitoclax 和 mTORC1/2 抑制剂 vistusertib 联合用药的疗效。

Scott, Susan C; Farago, Anna; Lai, W Victoria; Zahurak, Marianna; Rudek, Michelle A; Murray, Judy; Carducci, Michael A; Uziel, Tamar; Takebe, Naoko; Gore, Steven D; Rudin, Charles M; Hann, Christine L

Reversible chemoresistance of pancreatic cancer grown as spheroids

胰腺癌细胞球体培养的可逆性化疗耐药性

Matsushita, Yoshihisa; Norris, Alexis; Zhong, Yi; Begum, Asma; Liang, Hong; Debeljak, Marija; Anders, Nicole; Goggins, Michael; Rasheed, Zeshaan A; Hruban, Ralph H; Wolfgang, Christopher L; Thompson, Elizabeth D; Rudek, Michelle A; Liu, Jun O; Cope, Leslie; Eshleman, James R

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.

恩替诺特、纳武利尤单抗和伊匹木单抗治疗晚期 HER2 阴性乳腺癌女性:一项 Ib 期试验

Roussos Torres Evanthia T, Ho Won J, Danilova Ludmila, Tandurella Joseph A, Leatherman James, Rafie Christine, Wang Chenguang, Brufsky Adam, LoRusso Patricia, Chung Vincent, Yuan Yuan, Downs Melinda, O'Connor Ashley, Shin Sarah M, Hernandez Alexei, Engle Elizabeth L, Piekarz Richard, Streicher Howard, Talebi Zahra, Rudek Michelle A, Zhu Qingfeng, Anders Robert A, Cimino-Mathews Ashley, Fertig Elana J, Jaffee Elizabeth M, Stearns Vered, Connolly Roisin M

Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma

Encorafenib 和 Binimetinib 治疗 BRAF-V600E 突变型高级别胶质瘤的反应率及分子相关性

Schreck, Karisa C; Strowd, Roy E; Nabors, Louis B; Ellingson, Benjamin M; Chang, Michael; Tan, Sze K; Abdullaev, Zied; Turakulov, Rust; Aldape, Kenneth; Danda, Neeraja; Desideri, Serena; Fisher, Joy; Iacoboni, Michaella; Surakus, Trisha; Rudek, Michelle A; Bettegowda, Chetan; Grossman, Stuart A; Ye, Xiaobu

Nelfinavir inhibition of Kaposi's sarcoma-associated herpesvirus protein expression and capsid assembly

奈非那韦抑制卡波西肉瘤相关疱疹病毒蛋白表达和衣壳组装

Li, Maggie; Smith, Barbara J; Lee, Jaeyeun; Petr, Jennifer; Anders, Nicole M; Wiseman, Robyn; Rudek, Michelle A; Ambinder, Richard F; Desai, Prashant J

DPYD Testing: Time to Put Patient Safety First

DPYD 检测:是时候把患者安全放在首位了

Baker, Sharyn D; Bates, Susan E; Brooks, Gabriel A; Dahut, William L; Diasio, Robert B; El-Deiry, Wafik S; Evans, William E; Figg, William D; Hertz, Dan L; Hicks, J Kevin; Kamath, Suneel; Kasi, Pashtoon Murtaza; Knepper, Todd C; McLeod, Howard L; O'Donnell, Peter H; Relling, Mary V; Rudek, Michelle A; Sissung, Tristan M; Smith, D Max; Sparreboom, Alex; Swain, Sandra M; Walko, Christine M

Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

Brentuximab vedotin联合AVD治疗II-IV期HIV相关霍奇金淋巴瘤(AMC 085):一项开放标签、单臂、多中心1/2期试验的2期结果

Rubinstein, Paul G; Moore, Page C; Bimali, Milan; Lee, Jeanette Y; Rudek, Michelle A; Chadburn, Amy; Ratner, Lee; Henry, David H; Cesarman, Ethel; DeMarco, Camille E; Costagliola, Dominique; Taoufik, Yassine; Ramos, Juan Carlos; Sharon, Elad; Reid, Erin G; Ambinder, Richard F; Mitsuyasu, Ronald; Mounier, Nicolas; Besson, Caroline; Noy, Ariela

Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)

多激酶抑制剂卡博替尼(CYP3A4 底物)联合 CYP3A4 相互作用抗逆转录病毒疗法治疗 HIV 合并癌症患者的 I 期试验 (AMC-087)

Haigentz, Missak Jr; Lee, Jeannette Y; Chiao, Elizabeth Y; Aboulafia, David M; Ratner, Lee; Ambinder, Richard F; Baiocchi, Robert A; Mitsuyasu, Ronald T; Wachsman, William; Sparano, Joseph A; Rudek, Michelle A